Answers are grounded in this paper and cite their sources.
Introduction: Intravenous leiomyomatosis (IVLM) occurs when a leiomyoma arises from uterine smooth muscle cells and extends into the veins. It is rare and is often difficult to treat. We report a case of leiomyoma that extended into the ovarian and internal iliac veins and pelvic cavity, which was successfully resected after multidisciplinary treatment. Patient concerns: A 49-year-old, premenopausal Chinese woman was referred to our department after a follow-up for uterine myoma revealed a sudden increase in size of the pelvic tumor with intravascular growth. Diagnosis and Interventions: We suspected IVLM and administered relugolix (gonadotropin-releasing hormone antagonist) for 5 months. The tumor shrank by 76%. We selectively embolized the internal iliac and uterine arteries and performed a laparotomy, completely resecting the tumor. Relugolix was administered for 5 months postoperatively, then switched to the aromatase inhibitor letrozole. Outcomes: At 14 months postoperatively, there was no evidence of recurrence. Conclusion: This is the first report demonstrating the efficacy of a gonadotropin-releasing hormone antagonist for IVLM. Preoperative relugolix therapy followed by radical surgery is a promising strategy for patients with IVLM.
No takes yet. Share an insight, caveat, or question.
Nagashima et al. (2021) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: